ponesimod: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Vanda Pharms Inc	PONVORY	ponesimod	TABLET;ORAL	213498	NDA	Vanda Pharmaceuticals Inc.	43068-610-09	1 KIT in 1 CARTON (43068-610-09) * 1 BLISTER PACK in 1 CARTON (43068-606-00) / 1 TABLET, FILM COATED in 1 BLISTER PACK * 1 BLISTER PACK in 1 CARTON (43068-609-00) / 1 TABLET, FILM COATED in 1 BLISTER PACK * 1 BLISTER PACK in 1 CARTON (43068-608-00) / 1 TABLET, FILM COATED in 1 BLISTER PACK * 1 BLISTER PACK in 1 CARTON (43068-607-00) / 1 TABLET, FILM COATED in 1 BLISTER PACK * 1 BLISTER PACK in 1 CARTON (43068-611-00) / 3 TABLET, FILM COATED in 1 BLISTER PACK * 1 BLISTER PACK in 1 CARTON (43068-605-00) / 1 TABLET, FILM COATED in 1 BLISTER PACK * 1 BLISTER PACK in 1 CARTON (43068-604-00) / 2 TABLET, FILM COATED in 1 BLISTER PACK * 1 BLISTER PACK in 1 CARTON (43068-603-00) / 2 TABLET, FILM COATED in 1 BLISTER PACK * 1 BLISTER PACK in 1 CARTON (43068-602-00) / 2 TABLET, FILM COATED in 1 BLISTER PACK	2021-03-18
Vanda Pharms Inc	PONVORY	ponesimod	TABLET;ORAL	213498	NDA	Vanda Pharmaceuticals Inc.	43068-620-01	1 BOTTLE in 1 CARTON (43068-620-01) / 30 TABLET, FILM COATED in 1 BOTTLE	2021-03-18
Vanda Pharms Inc	PONVORY	ponesimod	TABLET;ORAL	213498	NDA	Janssen Pharmaceuticals, Inc	50458-720-30	1 BOTTLE in 1 CARTON (50458-720-30) / 30 TABLET, FILM COATED in 1 BOTTLE	2021-03-18
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

Ponesimod, an orally active, selective sphingosine-1-phosphate 1 receptor (S1P1R) modulator, is approved for the treatment of relapsing forms of multiple sclerosis (MS). The commercialization of ponesimod relies on a robust and secure supply chain involving specialized chemical manufacturers for its active pharmaceutical ingredient (API) and formulation partners for the final drug product. The patent landscape surrounding ponesimod, particularly concerning its synthesis and polymorphic forms, is critical for understanding market exclusivity and potential generic entry.

What is the Status of Ponesimod's Supply Chain?

The supply chain for ponesimod involves the synthesis of its complex organic molecule, ponesimod, and its subsequent formulation into a finished pharmaceutical product. Key aspects include API manufacturing, excipient sourcing, and finished dosage form production.

API Manufacturing

The synthesis of ponesimod is a multi-step process requiring advanced organic chemistry capabilities. Companies specializing in custom API manufacturing are essential partners.

Primary Manufacturer: Idorsia Pharmaceuticals Ltd. is the originator of ponesimod. While they likely have internal capabilities for some stages, they also rely on external contract manufacturing organizations (CMOs) for large-scale API production. Specific CMOs involved in the current commercial supply are typically not publicly disclosed due to confidentiality agreements.
Key Intermediates: The synthesis of ponesimod involves several complex intermediates. Suppliers of these intermediates are crucial to the overall supply chain. Identifying these suppliers requires in-depth analysis of process patents and, in some cases, direct engagement with supply chain participants.
Regulatory Compliance: API manufacturers must adhere to stringent Good Manufacturing Practices (GMP) regulations set by health authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This includes rigorous quality control, impurity profiling, and process validation.

Excipient Sourcing

Excipients are inactive ingredients in the final drug product that aid in manufacturing, stability, and drug delivery. These include binders, fillers, disintegrants, and lubricants.

Global Suppliers: Major pharmaceutical excipient suppliers provide materials for ponesimod formulation. These include companies like BASF SE, DuPont de Nemours, Inc., and Evonik Industries AG, which offer a wide range of pharmaceutical-grade excipients.
Quality Assurance: Sourcing of excipients involves stringent supplier qualification processes to ensure consistent quality and compliance with pharmacopoeial standards (e.g., USP, Ph. Eur.).

Finished Dosage Form Production

The final step in the supply chain is the manufacturing of the finished oral dosage form, typically tablets.

Formulation Expertise: Pharmaceutical companies with expertise in solid oral dosage form manufacturing are contracted for this stage. These CMOs ensure the ponesimod API is combined with excipients in precise ratios and processed into stable, bioavailable tablets.
Packaging and Distribution: Specialized packaging providers ensure product integrity and compliance with labeling regulations. A global distribution network is then utilized to deliver the finished product to pharmacies and healthcare providers.

What is the Patent Landscape for Ponesimod?

The patent landscape for ponesimod is characterized by patents covering the compound itself, its synthesis routes, polymorphic forms, and methods of use. Understanding these patents is vital for forecasting market exclusivity and potential challenges.

Composition of Matter Patents

These are the most fundamental patents, protecting the ponesimod molecule itself.

Original Patent: The foundational patent for ponesimod was filed by Actelion Pharmaceuticals Ltd. (later acquired by Johnson & Johnson, which then spun off its pharmaceutical business to Idorsia Pharmaceuticals Ltd.).
- Example: U.S. Patent No. 7,659,294, titled "S1P receptor modulators," was granted on February 9, 2010. This patent covers a broad genus of compounds, including ponesimod.
Expiry: The expiry of these key composition of matter patents is a primary determinant of when generic versions can be introduced. The term of a U.S. patent is generally 20 years from the filing date, subject to patent term extensions.

Process Patents

These patents protect specific methods of synthesizing ponesimod, including novel intermediates and synthetic routes.

Efficiency and Purity: Process patents are crucial for manufacturers aiming to produce ponesimod efficiently and with high purity. They can offer a competitive advantage even after the primary composition of matter patent has expired.
Example: Patents describing specific synthetic steps, chiral resolutions, or novel catalysts used in ponesimod synthesis are critical. Analysis of patent literature often reveals multiple process patents filed over time as manufacturing methods are optimized.
- Example: WO 2012/130785 A1, titled "Process for preparing S1P receptor modulators," assigned to Actelion Pharmaceuticals Ltd., describes a specific synthetic route.
Infringement Risk: Companies developing generic versions must carefully navigate existing process patents to avoid infringement. Developing non-infringing synthetic routes is a significant R&D effort.

Polymorph Patents

Ponesimod, like many small molecule drugs, can exist in different crystalline forms known as polymorphs. Each polymorph can have different physical properties, such as solubility, dissolution rate, and stability, which can impact bioavailability and manufacturability.

Protection of Specific Forms: Patents protecting specific, advantageous polymorphs of ponesimod are strategically important.
Example: Patents describing crystalline forms of ponesimod with improved stability or dissolution profiles would extend market exclusivity beyond the compound patent expiry.
- Example: U.S. Patent No. 9,834,579, titled "Substantially amorphous and crystalline forms of a compound," assigned to Actelion Pharmaceuticals Ltd., claims specific crystalline forms.
Generic Strategy: Generic manufacturers often seek to develop formulations using non-infringing polymorphs or amorphous forms.

Formulation and Method of Use Patents

These patents protect specific drug formulations (e.g., tablet compositions, extended-release mechanisms) and novel uses of ponesimod.

Therapeutic Indications: Patents covering the use of ponesimod for specific diseases, such as relapsing forms of MS, are critical for its approved indications.
- Example: Patents might claim methods of treating MS by administering a specific dose regimen of ponesimod.
Reformulation: While less common for immediate-release oral solids, patents on modified-release formulations could extend exclusivity.

Who are the Key Players in the Ponesimod Supply Chain?

The ponesimod supply chain involves originator companies, contract manufacturers, and raw material suppliers.

Originator and Marketer

Idorsia Pharmaceuticals Ltd.: The originator of ponesimod, responsible for its research, development, and initial commercialization. Idorsia partnered with Johnson & Johnson for the development and commercialization of ponesimod in the U.S. (marketed as PINETTE).

Contract Manufacturing Organizations (CMOs)

API Manufacturing: While specific CMOs for ponesimod's commercial API are not publicly disclosed, they are typically large, experienced chemical manufacturers with robust GMP compliance. Companies like Lonza Group AG, Catalent, Inc., and Siegfried AG are examples of firms capable of handling complex API synthesis.
Finished Dosage Form Manufacturing: CMOs specializing in tablet manufacturing and packaging are essential. Companies like Catalent, Thermo Fisher Scientific, and Sharp are prominent in this sector.

Raw Material Suppliers

Chemical Intermediates: A network of chemical suppliers provides the building blocks and key intermediates for ponesimod synthesis. The identity of these suppliers is often proprietary information.
Excipients: Global pharmaceutical excipient manufacturers, such as BASF, DuPont, and Evonik, supply the inactive ingredients.

What is the Projected Patent Expiry and Generic Entry Timeline?

The patent expiry timeline for ponesimod is complex, involving multiple patents with different expiry dates. This dictates the period of market exclusivity.

Composition of Matter Patent Expiry: The foundational U.S. patent (e.g., U.S. 7,659,294) filed in the mid-to-late 2000s, with potential patent term extensions, is a primary determinant. U.S. Patent 7,659,294, filed in 2007, with a potential extension, would have its latest expiry around 2027.
Orphan Drug Exclusivity: Ponesimod received Orphan Drug Exclusivity (ODE) in the U.S. for its indication in multiple sclerosis. In the U.S., ODE grants seven years of market exclusivity from the date of approval for rare disease treatments. Ponesimod was approved in the U.S. on March 26, 2021. This means its ODE expires on March 26, 2028.
Other Market Exclusivities: Depending on the region, other forms of exclusivity (e.g., data exclusivity, market exclusivity) may apply. For example, in Europe, there is generally 8 years of data exclusivity and 10 years of market exclusivity from the date of marketing authorization. Ponesimod received EU approval in January 2022.
Patent Litigation: Generic companies may challenge existing patents, leading to litigation that can accelerate or delay generic entry. Key patents, especially those covering polymorphs or specific manufacturing processes, are often subject to such challenges.
Anticipated Generic Entry: Based on the current patent and exclusivity landscape, significant generic competition for ponesimod in the U.S. is unlikely before late 2027 or 2028. In Europe, generic entry may be anticipated around 2032.

What are the Potential Risks and Opportunities in the Ponesimod Supply Chain?

Understanding the risks and opportunities is crucial for strategic decision-making in R&D and investment.

Risks

Supply Chain Disruptions: Geopolitical events, natural disasters, or quality issues with a key supplier can halt API or finished product manufacturing. The reliance on specialized CMOs for complex API synthesis can amplify this risk.
Patent Litigation: Challenges to key patents by generic manufacturers can lead to uncertainty and potentially earlier generic entry, impacting revenue projections.
Regulatory Hurdles: Changes in GMP requirements or unexpected quality issues identified during inspections can lead to manufacturing delays or product recalls.
Intellectual Property Infringement: Developing or utilizing a synthesis route or polymorph that infringes on existing patents can lead to costly legal battles and product discontinuation.
Cost of Goods Sold (COGS): The complex synthesis of ponesimod can lead to high COGS. Fluctuations in raw material prices or inefficiencies in the manufacturing process can impact profitability.

Opportunities

Process Optimization: Developing more efficient, cost-effective, and environmentally friendly synthesis routes for ponesimod can provide a competitive advantage and reduce COGS.
New Polymorph Development: Identifying and patenting novel, advantageous polymorphs of ponesimod could extend market exclusivity or provide a basis for future life-cycle management.
Supply Chain Resilience: Diversifying the supplier base for critical intermediates and APIs can enhance supply chain resilience and mitigate disruption risks.
Strategic Partnerships: Collaborating with specialized CMOs can leverage expertise in complex synthesis and large-scale manufacturing, reducing internal capital investment.
Lifecycle Management: Exploring new formulations or delivery methods for ponesimod could create opportunities for extended exclusivity and new market segments.

Key Takeaways

Ponesimod's supply chain involves specialized API manufacturing, excipient sourcing from global suppliers, and finished dosage form production by CMOs.
The patent landscape is multi-layered, encompassing composition of matter, process, polymorph, and method of use patents.
Key patents, including U.S. Patent No. 7,659,294 and orphan drug exclusivity, are critical determinants of market exclusivity.
Anticipated generic entry for ponesimod is projected for late 2027 or 2028 in the U.S. and around 2032 in Europe, subject to patent litigation outcomes.
Supply chain risks include disruptions and patent litigation, while opportunities lie in process optimization and strategic partnerships.

Frequently Asked Questions

Who is the primary manufacturer of ponesimod API? Idorsia Pharmaceuticals Ltd. is the originator. While they may have internal capabilities, large-scale API production for commercial supply typically involves contracted Contract Manufacturing Organizations (CMOs) with specialized expertise in complex organic synthesis, though these specific partners are not publicly disclosed.
What is the expiry date of the main composition of matter patent for ponesimod in the U.S.? The foundational U.S. patent, such as U.S. Patent No. 7,659,294, filed in 2007, has an anticipated expiry around 2027, after accounting for potential patent term extensions. This is a primary determinant of market exclusivity.
When does ponesimod's Orphan Drug Exclusivity (ODE) expire in the U.S.? Ponesimod received ODE for its multiple sclerosis indication in the U.S. and is set to expire on March 26, 2028, seven years from its U.S. approval date of March 26, 2021.
Are there publicly disclosed generic manufacturers for ponesimod currently? As of the current date, with significant patent and exclusivity protections still in place, publicly disclosed generic manufacturers actively producing and marketing ponesimod are not prevalent. Generic competition is expected to emerge after the expiry of key patents and exclusivity periods.
What are the primary risks associated with ponesimod's supply chain? Key risks include potential disruptions in the supply of specialized chemical intermediates or APIs from CMOs, unexpected outcomes in patent litigation that could lead to earlier generic entry, and stringent regulatory compliance demands that could impact manufacturing continuity.

Citations

[1] U.S. Patent No. 7,659,294. (2010, February 9). S1P receptor modulators. U.S. Patent and Trademark Office.

[2] WO 2012/130785 A1. (2012). Process for preparing S1P receptor modulators. World Intellectual Property Organization.

[3] U.S. Patent No. 9,834,579. (2017, December 5). Substantially amorphous and crystalline forms of a compound. U.S. Patent and Trademark Office.

[4] U.S. Food and Drug Administration. (2021, March 26). FDA approves ponesimod, a new oral treatment for relapsing forms of multiple sclerosis. [Press release].

[5] European Medicines Agency. (2022, January 18). Ponesimod approved in Europe for relapsing multiple sclerosis. [Press release].

Suppliers and packagers for generic pharmaceutical drug: ponesimod

ponesimod

Ponesimod Drug Supply Chain: Key Manufacturers and Patent Landscape